Literature DB >> 18250413

Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase.

Amanda L Martin1, Matthew D Schwartz, Stephen C Jameson, Yoji Shimizu.   

Abstract

Chemokine-mediated T cell migration is essential to an optimal immune response. The p110gamma isoform of PI3K is activated by G protein-coupled receptors and regulates neutrophil and macrophage chemotaxis. We used p110gamma-deficient mice to examine the role of p110gamma in CD8 T cell migration and activation in response to viral challenge. Naive CD8 T cell migration in response to CCL21 in vitro and trafficking into secondary lymphoid organs in vivo was unaffected by the loss of p110gamma. Furthermore, loss of p110gamma did not affect CD8 T cell proliferation and effector cell differentiation in vitro in response to anti-CD3 stimulation or in vivo in response to vaccinia virus (VV) challenge. However, there was reduced migration of p110gamma knockout (p110gamma(-/-)) CD8 effector T cells into the peritoneum following i.p. challenge with VV. The role of p110gamma in CD8 effector T cell migration was intrinsic to T cells, as p110gamma(-/-) CD8 effector T cells exhibited impaired migration into the inflamed peritoneum following secondary transfer into wild-type recipients. In addition, p110gamma(-/-) CD8 effector T cells exhibited impaired migration in vitro in response to inflammatory chemoattractants. Although wild-type mice efficiently cleared VV at high viral doses, infection of p110gamma knockout mice resulted in visible illness and death less than a week after infection. Thus, p110gamma is dispensable for constitutive migration of naive CD8 T cells and subsequent activation and differentiation into effector CD8 T cells, but plays a central role in the migration of effector CD8 T cells into inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250413     DOI: 10.4049/jimmunol.180.4.2081

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Authors:  Shuo Wang; Christos Patsis; Antonis E Koromilas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites.

Authors:  Molly S Thomas; Jason S Mitchell; Christopher C DeNucci; Amanda L Martin; Yoji Shimizu
Journal:  J Leukoc Biol       Date:  2008-06-03       Impact factor: 4.962

3.  p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.

Authors:  Aurore Saudemont; Fabien Garçon; Hakim Yadi; Marta Roche-Molina; Nayoung Kim; Anne Segonds-Pichon; Alfonso Martín-Fontecha; Klaus Okkenhaug; Francesco Colucci
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

Review 4.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

Review 5.  Directional sensing during chemotaxis.

Authors:  Christopher Janetopoulos; Richard A Firtel
Journal:  FEBS Lett       Date:  2008-04-29       Impact factor: 4.124

6.  Inducible costimulator controls migration of T cells to the lungs via down-regulation of CCR7 and CD62L.

Authors:  Tamson V Moore; Bryan S Clay; Judy L Cannon; Alexander Histed; Rebecca A Shilling; Anne I Sperling
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-18       Impact factor: 6.914

Review 7.  Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.

Authors:  Edwin J Yoo; Christie A Ojiaku; Krishna Sunder; Reynold A Panettieri
Journal:  Am J Respir Cell Mol Biol       Date:  2017-06       Impact factor: 6.914

Review 8.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

Review 9.  PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Opin Investig Drugs       Date:  2017-10-06       Impact factor: 6.206

10.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.